WeTrials

Phase II Study of Olaparib in Combination With Pembrolizumab in Patients With Advanced Melanoma With Homologous Recombination (HR) Pathway Gene Mutation

What is this study?

This study is testing a combination of two medications, olaparib and pembrolizumab, for advanced skin cancer (melanoma). It aims to help patients whose cancer has specific gene changes and has continued to grow despite standard treatments.

Who can participate?

You may be eligible if you have advanced melanoma with a specific DNA repair gene mutation, and your previous treatments have stopped working or were too hard to tolerate. You also need to be well enough to go about your daily activities.

What will happen?

Participants will receive a combination of olaparib, a targeted medication, and pembrolizumab, an immunotherapy drug that helps your immune system fight the cancer. Your health and tumor size will be closely monitored through regular scans and check-ups.

Where and when?

The study has locations in San Francisco, California, and Houston, Texas, and its current recruitment status is unknown.

Key Points
  • 1Tests a combination of two cancer-fighting drugs: olaparib and pembrolizumab
  • 2Designed for patients with advanced melanoma and a specific gene mutation
  • 3For individuals whose previous treatments have stopped working

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Metastatic Melanoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.